Implementation and evaluation of an investigational drug service–led approach for concomitant medication reviews in clinical trials

Clicks: 1
ID: 317938
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #140 of 143 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 143 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
PURPOSE: This report describes the implementation, workflow structure, and outcomes of a centralized, investigational drug service (IDS)-led process for concomitant medication reviews in oncology clinical trials. This initiative aimed to improve standardization and enhance protocol compliance by transitioning initial concomitant medication review responsibilities to IDS pharmacists. SUMMARY: A dedicated IDS pharmacist role was established to support centralized concomitant medication reviews, ensuring a standardized and efficient process. This initiative included developing a structured request system, electronic documentation, and protocol-specific concomitant medication review guides to enhance consistency. Over a 24-month evaluation period, IDS pharmacists completed 1,052 concomitant medication reviews, averaging 43.8 reviews per month. Drug-drug interactions were identified in 34.3% of cases, with the highest prevalence observed in phase 1 trials. IDS review times remained consistent, with a mean system-tracked time of 1.31 hours per review. However, delays in medication reconciliation emerged as the primary bottleneck, often prolonging review completion. A financial analysis confirmed the program's sustainability, demonstrating that the billable fee-for-service model effectively supported its implementation. Despite these successes, challenges remained, including variability in protocol interpretation and limited guidance on herbal and supplement use. CONCLUSION: The IDS-led concomitant medication review model improved workflow standardization while supporting operational efficiency and financial sustainability. This approach provides a scalable framework that can be adapted to other clinical trial programs and expanded to include ongoing medication monitoring.
Reference Key
openalex_W7165119606 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors A Cameron Hill, Camryn Froerer
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag184
URL
https://doi.org/10.1093/ajhp/zxag184
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.